These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35014156)

  • 1. Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.
    Yadav Y; Dunagan K; Khot R; Venkatesh SK; Port J; Galderisi A; Cobelli C; Wegner C; Basu A; Carter R; Basu R
    Diabetes Obes Metab; 2022 May; 24(5):881-890. PubMed ID: 35014156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.
    Ajjan RA; Hensor EMA; Del Galdo F; Shams K; Abbas A; Fairclough RJ; Webber L; Pegg L; Freeman A; Taylor AE; Arlt W; Morgan AW; Tahrani AA; Stewart PM; Russell DA; Tiganescu A
    Eur J Endocrinol; 2022 Feb; 186(4):441-455. PubMed ID: 35113805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.
    Markey K; Mitchell J; Botfield H; Ottridge RS; Matthews T; Krishnan A; Woolley R; Westgate C; Yiangou A; Alimajstorovic Z; Shah P; Rick C; Ives N; Taylor AE; Gilligan LC; Jenkinson C; Arlt W; Scotton W; Fairclough RJ; Singhal R; Stewart PM; Tomlinson JW; Lavery GG; Mollan SP; Sinclair AJ
    Brain Commun; 2020; 2(1):fcz050. PubMed ID: 32954315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.
    Abbas A; Schini M; Ainsworth G; Brown SR; Oughton J; Crowley RK; Cooper MS; Fairclough RJ; Eastell R; Stewart PM
    J Clin Endocrinol Metab; 2022 Jun; 107(7):2026-2035. PubMed ID: 35275196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
    Hardy RS; Botfield H; Markey K; Mitchell JL; Alimajstorovic Z; Westgate CSJ; Sagmeister M; Fairclough RJ; Ottridge RS; Yiangou A; Storbeck KH; Taylor AE; Gilligan LC; Arlt W; Stewart PM; Tomlinson JW; Mollan SP; Lavery GG; Sinclair AJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):174-187. PubMed ID: 33098644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
    Stefan N; Ramsauer M; Jordan P; Nowotny B; Kantartzis K; Machann J; Hwang JH; Nowotny P; Kahl S; Harreiter J; Hornemann S; Sanyal AJ; Stewart PM; Pfeiffer AF; Kautzky-Willer A; Roden M; Häring HU; Fürst-Recktenwald S
    Lancet Diabetes Endocrinol; 2014 May; 2(5):406-16. PubMed ID: 24795254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
    Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
    Othonos N; Pofi R; Arvaniti A; White S; Bonaventura I; Nikolaou N; Moolla A; Marjot T; Stimson RH; van Beek AP; van Faassen M; Isidori AM; Bateman E; Sadler R; Karpe F; Stewart PM; Webster C; Duffy J; Eastell R; Gossiel F; Cornfield T; Hodson L; Jane Escott K; Whittaker A; Kirik U; Coleman RL; Scott CAB; Milton JE; Agbaje O; Holman RR; Tomlinson JW
    Nat Commun; 2023 Feb; 14(1):1025. PubMed ID: 36823106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.
    Ahmed A; Rabbitt E; Brady T; Brown C; Guest P; Bujalska IJ; Doig C; Newsome PN; Hubscher S; Elias E; Adams DH; Tomlinson JW; Stewart PM
    PLoS One; 2012; 7(2):e29531. PubMed ID: 22363403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
    N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
    Abdelmalek MF; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Lawitz EJ; Harrison SA; Jacobson IM; Imajo K; Gunn N; Halegoua-DeMarzio D; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Loomba R
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):113-123.e9. PubMed ID: 37088458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
    Larner DP; Morgan SA; Gathercole LL; Doig CL; Guest P; Weston C; Hazeldine J; Tomlinson JW; Stewart PM; Lavery GG
    Endocrinology; 2016 Sep; 157(9):3493-504. PubMed ID: 27384305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
    Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
    Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
    Loomba R; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Harrison SA; Lawitz EJ; Gunn N; Imajo K; Ravendhran N; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Abdelmalek MF
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):102-112.e9. PubMed ID: 37088457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
    Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.